A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a DH6-directed Antibody-drug Conjugate, in Subjects with Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer